Item 2(c).

```
Amendment No. 0
ALDEYRA THERAPEUTICS INC
COMMON STOCK
Cusip #01438T106
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
          Rule 13d-1(b)
[x]
          Rule 13d-1(c)
          Rule 13d-1(d)
Γ 1
Cusip #01438T106
Item 1:
                         Reporting Person - FMR LLC
Item 2:
                         (a)
                                 [ ]
                 (b)
                         [ ]
Item 4:
                         Delaware
Item 5:
                         0
Item 6:
                         0
Item 7:
                         775,000
Item 8:
Item 9:
                         775,000
Item 11:
                         14.168%
Item 12:
Cusip #01438T106
                         Reporting Person - Edward C. Johnson 3d
Item 1:
Item 2:
                         (a)
                                 [ ]
                 (b)
                         United States of America
Item 4:
Item 5:
Item 6:
                         775,000
Item 7:
Item 8:
Item 9:
                         775,000
Item 11:
                         14.168%
Item 12:
                         ΙN
Cusip #01438T106
Item 1:
                         Reporting Person - Abigail P. Johnson
Item 2:
                 (b)
Item 4:
                         United States of America
Item 5:
                         0
Item 6:
                         775,000
Item 7:
Item 8:
Item 9:
                         775,000
Item 11:
                         14.168%
Item 12:
Cusip #01438T106
Item 1:
                         Reporting Person - Fidelity Select Biotechnology
Portfolio
Item 2:
                         (a)
                                 [ ]
                 (b)
                         [ ]
Item 4:
                         Massachusetts
Item 5:
                         517,016
Item 6:
Item 7:
                         0
Item 8:
Item 9:
                         517,016
Item 11:
                         9.452%
Item 12:
Item 1(a).
                         Name of Issuer:
                                  ALDEYRA THERAPEUTICS INC
Item 1(b).
                         Address of Issuer's Principal Executive Offices:
                                  15 NEW ENGLAND EXECUTIVE PARK
                                  Burlington, MA 01803
                                  USA
Item 2(a).
                          Name of Person Filing:
                                  FMR LLC
                          Address or Principal Business Office or, if None,
Item 2(b).
Residence:
                                   245 Summer Street, Boston, Massachusetts 02210
```

Citizenship:

Not applicable

Item 2(d). Title of Class of Securities:

COMMON STOCK

Item 2(e). CUSIP Number:

01438T106

Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b)

or (c) and the

person filing, FMR LLC, is a parent holding company in accordance with

Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A).

Item 4. **Ownership** 

> Amount Beneficially Owned: (a) 775,000

Percent of Class: (b) 14.168%

(c) Number of shares as to which such person has:

> (i) sole power to vote or to direct the vote: Θ

> (ii) shared power to vote or to direct the vote:

(iii) sole power to dispose or to direct the

775,000

disposition of:

(iv) shared power to dispose or to direct the

disposition of:

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another

Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which

Acquired the Security Being Reported on By the Parent Holding Company.

See attached Exhibit A.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

> June 9, 2014 Date

/s/ Scott C. Goebel Signature

Scott C. Goebel
Duly authorized under Power of Attorney effective as of June 1, 2008, by and on behalf of FMR LLC and its direct and indirect subsidiaries.

Exhibit A

Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

Entity ITEM 3 Classification FMRCO., INC.  $^{\ast}$  IA

\* Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.

Edward C. Johnson 3d is a Director and the Chairman of FMR LLC and Abigail P. Johnson is a Director, the Vice Chairman and the President of FMR LLC.

Members of the family of Edward C. Johnson 3d, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC.

Neither FMR LLC nor Edward C. Johnson 3d nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company ("FMR Co"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. Fidelity Management & Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees.

This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998).

RULE 13d-1(k)(1) AGREEMENT

The undersigned persons, on June 9, 2014, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ALDEYRA THERAPEUTICS INC at May 30, 2014.

FMR LLC

By /s/ Scott C. Goebel Scott C. Goebel Duly authorized under Power of Attorney effective as of June 1, 2008, by and on behalf of FMR LLC and its direct and indirect subsidiaries By /s/ Scott C. Goebel Scott C. Goebel Duly authorized under Power of Attorney effective as of June 1, 2008, by and on behalf of Edward C. Johnson 3d

Abigail P. Johnson

By /s/ Scott C. Goebel Scott C. Goebel Duly authorized under Power of Attorney effective as of April 24, 2014, by and on behalf of Abigail P. Johnson

Fidelity Select Biotechnology Portfolio

By /s/ Scott C. Goebel Scott C. Goebel Secretary

Page of